Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2025

---

Rocket Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

---

---

---

Registrant’s telephone number, including area code: (646) 440-9100

---

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

---

In connection with the previously announced departure of Dr. Kinnari Patel to accept a role as a venture partner at RTW Investments LP, on September 11, 2025, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a Separation and Release Agreement (the “Separation Agreement”) with Dr. Patel. Pursuant to the Separation Agreement, Dr. Patel agreed to a general release of claims in favor of the Company and its affiliates and agreed to certain restrictive covenants.

The Separation Agreement also provides for the following:

On September 11, 2025, Dr. Patel and the Company entered into a Consulting Agreement to be effective beginning on the expiration of the revocation period provided for in the Release of Claims (the “Effective Date”). The Consulting Agreement shall begin on the Effective Date and continue through December 31, 2026 (the “Consulting Period”), unless earlier terminated by either party pursuant to the terms therein. The Company shall pay Dr. Patel an aggregate retainer fee of $582,156 under the Consulting Agreement and Dr. Patel shall provide such general consulting services as reasonably required by the Company. The Consulting Agreement also provides that Dr. Patel shall retain the restricted stock units and options through the Consulting Period granted under any and all Rocket Pharmaceuticals, Inc. Stock Option, Share Option, and Incentive Plans.

The foregoing summaries of the Separation Agreement and Consulting Agreement are qualified in their entirety by reference to the text of the documents, which are filed as Exhibits 10.1 and 10.2 hereto, respectively, and incorporated herein by reference.

(d) Exhibits

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---